“Global Defibrillators market set to grow to $15bn by 2024” says new Visiongain report

19 December 2018
Pharma

Visiongain has launched a new pharma report Global Defibrillators Market Forecast 2019-2029: External Defibrillators, Implantable Cardioverter Defibrillators, Transvenous ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, Automated External Defibrillators, Wearable Cardioverter Defibrillators.

Defibrillators are essential in improving the quality of life and overall well-being. The defibrillators industry is highly competitive and diverse with immense potential growth. Drivers for growth include availability of technologically advanced defibrillators, rapidly growing aging population leading to high risk of cardiovascular diseases, growing incidence of cardiovascular diseases and increasing awareness and training programmes related to defibrillators.

The lead analyst of the report commented "Growth in this market is set to be driven by the availability of technologically advanced defibrillators, rapidly growing aging population leading to high risk of cardiovascular diseases, growing incidence of cardiovascular diseases and increasing awareness and training programmes related to defibrillators. However, lack of awareness about sudden cardiac arrest, issues related to the use of defibrillator devices (external and implantable), and unfavourable healthcare reforms in the U.S. are some of the key factors restraining the growth of this market. In addition to this, increasing pricing pressure on market players and frequent product recalls pose major challenges to defibrillator manufacturers."

Leading companies featured in the report include Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, LivaNova PLC, Medtronic PLC, Nihon Kohden Corporation, Phillips Healthcare, Physio Control Inc., Zoll Medical Corporation.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Asthma & COPD market set to grow to $49 bn by 2025” says new Visiongain report

The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.

17 February 2020

Read

“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.

17 February 2020

Read

Visiongain assesses that the Contract Research Organisations (CROs) market will generate revenues of $38.0 billion in 2020

Global clinical research organizations market was valued at $34.9 billion in 2019 and is projected to grow at a CAGR of 9.5% during the forecast period 2020-2030.

12 February 2020

Read

“Translational Regenerative Medicine market set to grow to $118bn by 2025” says new Visiongain report

The translational regenerative medicine market is expected to grow significantly due to the advances in technology and improvements in regulatory frameworks.

03 February 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever